Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease

Journal of Neuroscience

Volumn 29, Issue 33, 2009, Pages 10371-10386

  Cummings, Damian M ^a   André, Véronique M ^a   Uzgil, Besim O ^a   Gee, Steven M ^a   Fisher, Yvette E ^a   Cepeda, Carlos ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; TETRODOTOXIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GENETIC MODEL; HUNTINGTON CHOREA; IN VIVO STUDY; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SEIZURE; SOMATOSENSORY CORTEX; SYNAPTIC TRANSMISSION;

ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; NEURAL INHIBITION; PYRAMIDAL CELLS; SYNAPTIC POTENTIALS;

EID: 69049091946     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1592-09.2009     Document Type: Article

References (69)

1. André VM, Cepeda C, Venegas A, Gomez Y, Levine MS (2006) Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol 95:2108-2119.
2. Ariano MA, Cepeda C, Calvert CR, Flores-Hernández J, Hernández-Echeagaray E, Klapstein GJ, Chandler SH, Aronin N, DiFiglia M, Levine MS (2005) Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 93:2565-2574.
3. Bäckman L, Farde L (2001) Dopamine and cognitive functioning: Brain imaging findings in Huntington's disease and normal aging. Scand J Psychol 42:287-296.
4. Bates G, Harper PS, Jones L (2002) Huntington's disease, Ed 3. Oxford: Oxford UP.
5. Bates GP, Murphy KPSJ (2002) Mouse models of Huntington's disease. In: Huntington's disease, Ed 3 (Bates GP, Harper PS, Jones L, eds), pp 387-426. Oxford: Oxford UP.
6. Bekkers JM, Stevens CF (1990) Presynaptic mechanism for long-term potentiation in the hippocampus. Nature 346:724-729.
7. Berrios GE, Wagle AC, Marková IS, Wagle SA, Rosser A, Hodges JR (2002) Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand 105:224-230.
8. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257.
9. Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66:525-539.
10. Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23:961-969.
11. Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, André VM, Ariano MA, Levine MS (2004) Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78:855-867.
12. Cepeda C, Wu N, André VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81:253-271.
13. Choi S, Lovinger DM (1997) Decreased probability of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses. Proc Natl Acad Sci U S A 94:2665-2670.
14. Clark KA, Randall AD, Collingridge GL (1994) A comparison of paired-pulsed facilitation of AMPA and NMDA receptor-mediated excitatory postsynaptic currents in the hippocampus. Exp Brain Res 101:272-278.
15. Cummings DM, Milnerwood AJ, Dallérac GM, Waights V, Brown JY, Vatsavayai SC, Hirst MC, Murphy KPSJ (2006) Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 15:2856-2868.
16. Cummings DM, Milnerwood AJ, Dallérac GM, Vatsavayai SC, Hirst MC, Murphy KPSJ (2007) Abnormal cortical synaptic plasticity in mice transgenic for exon 1 of the human Huntington's disease mutation. Brain Res Bull 72:103-107.
17. Cummings DM, Yim MM, Alaghband Y, Malvar JS, Tsuruyama K, Joshi PR, Cepeda C, Levine MS (2008) The R6/2 phenotype is CAG repeat length-dependent. Soc Neurosci Abstr 34:443.011.
18. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB (1985) Selective sparing of a class of striatal neurons in Huntington's disease. Science 230:561-563.
19. Gambardella A, Muglia M, Labate A, Magariello A, Gabriele AL, Mazzei R, Pirritano D, Conforti FL, Patitucci A, Valentino P, Zappia M, Quattrone A (2001) Juvenile Huntington's disease presenting as progressive myoclonic epilepsy. Neurology 57:708-711.
20. Garthwaite J (1994) NMDA receptors, neuronal development, and neurodegeneration. The NMDA receptor (Collingridge GL, Watkins JC, eds), pp 428-456. Oxford: Oxford UP.
21. Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, Heintz N, Yang XW (2005) Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46:433-444.
22. Hansen SL, Fjalland B, Jackson MB (1999) Differential blockade of gamma-aminobutyric acid type A receptors by the neuroactive steroid dehydroepiandrosterone sulfate in posterior and intermediate pituitary. Mol Pharmacol 55:489-496.
23. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal loss in knock-in Huntington's disease mice. Neuroscience 157:280-295.
24. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, Olson JM, Jones L, Luthi-Carter R (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15:965-977.
25. Horikawa K, Armstrong WE (1988) A versatile means of intracellular labeling: injection of biocytin and its detection with avidin conjugates. J Neurosci Methods 25:1-11.
26. Huang K, Yanai A, Kang R, Arstikaitis P, Singaraja RR, Metzler M, Mullard A, Haigh B, Gauthier-Campbell C, Gutekunst CA, Hayden MR, El-Husseini A (2004) Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron 44:977-986.
27. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
28. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86:2667-2677.
29. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58:515-532.
30. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF (2004) Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27:691-697.
31. Li H, Wyman T, Yu ZX, Li SH, Li XJ (2003) Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 12:2021-2030.
32. Liévens JC, Woodman B, Mahal A, Bates GP (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 20:638-648.
33. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19:10428-10437.
34. Malinow R, Tsien RW (1990) Presynaptic enhancement shown by wholecell recordings of long-term potentiation in hippocampal slices. Nature 346:177-180.
35. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
36. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C (2004) Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 5:793-807.
37. Martínez-Torres A, Demuro A, Miledi R (2000) GABArho 1/GABAAalpha 1 receptor chimeras to study receptor desensitization. Proc Natl Acad Sci U S A 97:3562-3566.
38. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 30:293-302.
39. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465:11-26.
40. Metzler M, Legendre-Guillemin V, Gan L, Chopra V, Kwok A, McPherson PS, Hayden MR (2001) HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem 276:39271-39276.
41. Milner AJ, Cummings DM, Spencer JP, Murphy KPSJ (2004) Bi-directional plasticity and age-dependent long-term depression at mouse CA3-CA1 hippocampal synapses. Neurosci Lett 367:1-5.
42. Milnerwood AJ, Cummings DM, Dallérac GM, Brown JY, Vatsavayai SC, Hirst MC, Rezaie P, Murphy KP (2006) Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 15:1690-1703.
43. Morton AJ, Faull RL, Edwardson JM (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res Bull 56:111-117.
44. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20:5115-5123.
45. Nisenbaum ES, Wilson CJ (1995) Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons. J Neurosci 15:4449-4463.
46. A receptor alpha subunits expression with the properties of IPSCs in the developing thalamus. J Neurosci 20:2202-2208.
47. Pallier PN, Maywood ES, Zheng Z, Chesham JE, Inyushkin AN, Dyball R, Hastings MH, Morton AJ (2007) Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci 27:7869-7878.
48. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington's disease decades before diagnosis: the predict HD study. J Neurol Neurosurg Psychiatry 79:874-880.
49. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
50. Reyes A, Galarraga E, Flores-Hernández J, Tapia D, Bargas J (1998) Passive properties of neostriatal neurons during potassium conductance blockade. Exp Brain Res 120:70-84.
51. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745-747.
52. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM (2008) Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 131:1057-1068.
53. Rossi S, Prosperetti C, Picconi B, De Chiara V, Mataluni G, Bernardi G, Calabresi P, Centonze D (2006) Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. Neurosci Lett 410:6-10.
54. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, Maciocco E, Biggio G (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 451:103-110.
55. Seneca S, Fagnart D, Keymolen K, Lissens W, Hasaerts D, Debulpaep S, Desprechins B, Liebaers I, De Meirleir L (2004) Early onset Huntington disease: a neuronal degeneration syndrome. Eur J Pediatr 163:717-721.
56. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567.
57. Spampanato J, Gu X, Yang XW, Mody I (2008) Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 157:606-620.
58. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 490:354-370.
59. Starling AJ, André VM, Cepeda C, de Lima M, Chandler SH, Levine MS (2005) Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 82:377-386.
60. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 97:8093-8097.
61. Uchimura N, Cherubini E, North RA (1989) Inward rectification in rat nucleus accumbens neurons. J Neurophysiol 62:1280-1286.
62. A receptor α1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J Neurosci 21:3009-3016.
63. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
64. (Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72:83-97.
65. Yohrling IV GJ, Cha JH (2002) Neurochemistry of Huntington's disease. In: Huntington's disease, Ed 3 (Bates GP, Harper PS, Jones L, eds), pp 276-308. Oxford: Oxford UP.
66. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-D- aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33:849-860.
67. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci 25:469-479.
68. Zhang HG, Lee HJ, Rocheleau T, ffrench-Constant RH, Jackson MB (1995) Subunit composition determines picrotoxin and bicuculline sensitivity of Drosophila gamma-aminobutyric acid receptors. Mol Pharmacol 48:835-840.
69. Zucker RS (1989) Short-term synaptic plasticity. Annu Rev Neurosci 12:13-31.